Cara Therapeutics price target lowered to $25 from $28 at Stifel

Stifel analyst Annabel Samimy lowered the firm’s price target on Cara Therapeutics to $25 from $28 and keeps a Buy rating on the shares. Accelerating demand is beginning to emerge and the company believes inventories at all clinics will be depleted by the end of the year, the analyst tells investors. Further, CMS has proposed some new post-TDAPA rules, which are currently better than what the stock implies, but utilization under this scenario will still be challenging, Stifel says.